- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Digital Breast Tomosynthesis Doses Comparable to Mammography
Radiation doses from digital breast tomosynthesis is comparable to and could be lower than conventional two-view full-field digital mammography.
Radiation doses from digital breast tomosynthesis is comparable to and could be lower than conventional two-view full-field digital mammography, show findings of a study published in the April issue of Radiology.
Researchers from Emory University School of Medicine in Atlanta, Ga., compared dose levels of digital breast tomosynthesis (DBT) and full-field digital mammography (FFDM) by using compressible water-oil mixture breast phantoms of varying sizes to determine how much radiation dose would be used for varying sizes and glandular compositions of breasts.
When comparing doses with the “average” breast (compressed thickness of 5 cm, 50 percent glandular fraction), a DBT acquisition resulted in 1.30 mGy, only an 8 percent higher mean glandular dose than the FFDM acquisition of 1.20 mGy. For a thicker breast sample (6.0 cm and 14.3 percent glandular fraction), a DBT acquisition was 2.12 mGy, which was 83 percent higher than an FFDM acquisition of 1.16 mGy.
RELATED: Practices Adjust Workflow IT for Tomosynthesis Adoption
Although the thicker breast had a higher dose, the researchers pointed out that this was still lower than the 3 mGy limit for a single-view conventional study, which is set by the Mammography Quality Standards Act.
Potentially, screening DBT could reduce the recall rate, reducing the number of repeat scans, which reduces women’s overall radiation dose rate.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
